SGSandhya Girish

Sandhya Girish

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandhya Girish has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacokinetics, Safety, and Tolerability of GS‐1427, an Oral Prodrug of a Potent and Selective α4β7 Integrin Inhibitor, in Healthy Participants

    by Jin Zhou, Neeraja Maramreddy, John McFarlane, Yan Zhou, Frank Hong, Sandhya Girish

    GS‐1427 is the oral prodrug of GS‐1069518, an inhibitor of the α4β7 integrin, and is currently in development for the treatment of ulcerative colitis (UC). This first‐in‐human, phase 1, placebo‐controlled study evaluated the pharmacokinetics, safety, and tolerability of GS‐1427 and GS‐1069518 after single oral doses (20‐1000 mg) or multiple once‐daily doses (20‐500 mg) of GS‐1427 for 14 days. The bioavailability of tablet versus capsule formulations and the effect of food and an acid‐reducing agent (omeprazole) on exposure were also assessed. Overall, 148 healthy participants were enrolled, and 143 completed the study. GS‐1427 was quickly converted to GS‐1069518 during absorption. Upon repeated once‐daily dosing of GS‐1427 under nonfasting conditions, steady‐state exposure to GS‐1069518 was reached by day 5 with limited accumulation observed. At steady state, the median time to maximum concentration for GS‐1069518 was 1‐3 h and the mean terminal half‐life was 6.7‐28.3 h. Bioavailability was lower in the tablet than in capsule formulation. Food intake and omeprazole coadministration reduced the exposure to GS‐1069518 by approximately 20%‐40%. Overall, 26/122 participants (21.3%) who received GS‐1427 and 8/26 participants (30.1%) who received placebo experienced at least one treatment‐emergent adverse event (AE). Of the 148 participants, 10 (6.8%) experienced a treatment‐related AE, the most common being nausea (5/148, 3.4%) and diarrhea (3/148, 2.0%). All AEs were grade 1 in severity and no serious AEs or deaths were reported. The pharmacokinetics, safety, and tolerability results from this study support further evaluation of GS‐1427 in a phase 2 trial in patients with UC.

  • Open Access

    Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR +/ HER2 − Metastatic Breast Cancer Data From the Phase 3 TROPiCS ‐02 Trial

    by Abhishek G. Sathe, Aksana K. Jones, Paul M. Diderichsen, Xiaohui Wang, Peter Chang, Wendy Verret, Sandhya Girish

    Sacituzumab govitecan (SG) is an antibody–drug conjugate composed of a Trop‐2–directed antibody coupled to SN‐38. SG is approved in multiple countries for pretreated metastatic triple‐negative breast cancer (mTNBC) and hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2–) mBC. Three previously developed population pharmacokinetic (PopPK) models for SG, free SN‐38, and total antibody (tAB) in patients with mTNBC or other solid tumors were externally validated using data from 260 patients with HR+/HER2− mBC from TROPiCS‐02 (NCT03901339). Pharmacokinetic parameters were re‐estimated using data from 789 patients with HR+/HER2− mBC, mTNBC, or other solid tumors from three studies—TROPiCS‐02, ASCENT (NCT02574455), and IMMU‐132‐01 (NCT01631552). Previously developed PopPK models adequately described the data from TROPiCS‐02. Typical parameter estimates based on combined dataset for clearance and steady‐state volume of distribution were 0.128 L/h and 3.58 L for SG and 0.0155 L/h and 4.29 L for tAB, respectively. The pharmacokinetics of the three analytes (SG, free SN‐38, and tAB) in participants with HR+/HER2− mBC were consistent with those observed in mTNBC and other tumor types. The analyses confirmed mild‐to‐moderate renal impairment, mild hepatic impairment, age, tumor type (based on limited data in non‐breast cancer tumor types), baseline albumin level, UGT1A1 genotype, or Trop‐2 expression did not have a clinically relevant impact on the exposure of the three analytes across populations. These findings support that the SG dosing regimen of 10 mg/kg on Days 1 and 8 of 21‐day cycles is adequate for patients with HR+/HER2− mBC.


  • Open Access

    Modeling the Interplay Between Viral and Immune Dynamics in HIV: A Review and Mrgsolve Implementation and Exploration

    by Alberto Vegas Rodriguez, Nieves Velez de Mendizábal, Sandhya Girish, Iñaki F. Trocóniz, Justin S. Feigelman

    Since its initial discovery, HIV has infected more than 70 million individuals globally, leading to the deaths of 35 million. At present, the annual number of deaths has significantly decreased due to 75% of HIV‐positive individuals being on antiretroviral therapy. Although there is no cure yet, available treatments extend life expectancy, enhance quality of life, and reduce transmission by maintaining viral load below the detection limit of 50 copies/mL, making the individual's levels undetectable and untransmittable. HIV has attracted considerable attention in the computational modeling area, with various models having been developed with different degrees of complexity in an attempt to explain the viral dynamics of the disease. It is important to note that no single model can fully incorporate and predict all the critical factors influencing the dynamics of the disease and its response to treatments. Since the number of published models is large, the purpose of this article is to review several relevant models found in the literature that describe biologically plausible scenarios of HIV infection, including key features of disease progression with or without treatment. A total of 15 models are described, with some implemented in the mrgsolve package in R Studio and shared for the benefit of the scientific community. The modeling framework concerning HIV infection aids in identifying the most impactful parameters within the system and their implications in the model outcomes. Insights provided by these models may help in confirming targets for current and novel therapies, thereby contributing to the exploration of new strategies.


  • Open Access

    Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer

    by Abhishek G. Sathe, Paul M. Diderichsen, Floris Fauchet, See‐Chun Phan, Sandhya Girish, Ahmed A. Othman

    Sacituzumab govitecan (SG), a Trop‐2‐directed antibody‐drug conjugate, is approved for patients with metastatic triple‐negative breast cancer (mTNBC) who received ≥2 prior systemic therapies (≥1 in metastatic setting). Exposure–response (E‐R) relationships between SG exposure and efficacy and safety outcomes were characterized in 277 patients with mTNBC using data from the phase I/II IMMU‐132‐01 and phase III ASCENT (IMMU‐132‐05) studies. Evaluated endpoints included complete response (CR), objective response rate (ORR), progression‐free survival (PFS), overall survival (OS), and safety endpoints (individual first worst grade of select adverse events (AEs)). E‐R analyses were also conducted for time to first dose reduction or delay. Patients received SG at 8 or 10 mg/kg intravenously on days 1 and 8 of a 21‐day cycle. Average SG‐related serum exposure over the treatment duration (until the event) was consistently the most significant exposure metric correlated with efficacy and safety endpoints. Higher average concentration over the treatment duration for SG (CAVGSG) was the best predictor of CR and ORR. The model‐predicted proportions of patients with CR and ORR at 10 mg/kg were 4.26% and 32.6%, respectively. Higher CAVG for total antibody was the best predictor of OS and PFS. The model‐predicted probability of OS at 12 months at median lactate dehydrogenase (227 IU/L) was 53%. The probability of grade ≥1 evaluated AEs and the risk of dose reductions and delays significantly increased with increasing CAVGSG. The model‐predicted proportions of patients with any‐grade AEs were 35.9%, 67.4%, 64.7%, and 67.1% for vomiting, diarrhea, nausea, and neutropenia, respectively (10 mg/kg dose group). Neutropenia was the only evaluated AE for which CAVGSG was significantly associated with grade ≥3 events. The clinically meaningful efficacy and manageable safety achieved with SG 10 mg/kg on days 1 and 8 of every 21‐day cycle dosing regimen supports the appropriateness of this clinical dosage in patients with mTNBC.


  • Open Access

    Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium Perspective

    by Mohamed‐Eslam F. Mohamed, Sandhya Girish, Rita Humeniuk, Silpa Nuthalapati, Amit Desai, Amita Datta‐Mannan, Ferdous Gheyas, Jitendra Kanodia, Sravanthi Cheeti, Tong Zhu

  • Open Access

    Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants

    by Rita Humeniuk, Kavita Juneja, Shuguang Chen, Scott Ellis, Olena Anoshchenko, Deqing Xiao, Aaron Share, Matthew Johnston, Santosh Davies, Adam DeZure, et al.

    Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration routes, including localized pulmonary delivery, can lower systemic exposure and maximize exposure at the site of action. This study evaluated the pharmacokinetics (PK) and safety of inhaled RDV in healthy adults. This phase Ia, randomized, placebo‐controlled study evaluated inhaled RDV in healthy participants randomized 4:1 to receive RDV or placebo as single doses (4 cohorts) or multiple once‐daily doses (3 cohorts). Doses in cohorts 1–6 were administered as an aerosolized solution for inhalation through a sealed facemask; doses in cohort 7 were administered as an aerosolized solution for inhalation through a mouthpiece. Safety was assessed throughout the study. Seventy‐two participants were enrolled (inhaled RDV, n = 58 and placebo, n = 14). Following single RDV doses, RDV, GS‐704277, and GS‐441524 plasma PK parameters indicated dose‐proportional increases in area under the concentration‐time curve (AUC) extrapolated to infinite time, AUC from time zero to last quantifiable concentration, and maximum observed concentration. Analyte plasma concentrations after multiple RDV doses were consistent with those for single‐dose RDV. Analyte plasma exposures were lower when RDV was administered with a mouthpiece versus a sealed facemask. The most common adverse events included nausea, dizziness, and cough. Single‐ and multiple‐dose inhaled RDV exhibited linear and dose‐proportional plasma PK. Administration of RDV via inhalation was generally safe and well‐tolerated.


  • Open Access

    Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy

    by Sreeneeranj Kasichayanula, Sandhya Mandlekar, Vittal Shivva, Maulik Patel, Sandhya Girish

    Cancer immunotherapy has significantly advanced the treatment paradigm in oncology, with approvals of immuno‐oncology agents for over 16 indications, many of them first line. Checkpoint inhibitors (CPIs) are recognized as an essential backbone for a successful anticancer therapy regimen. This review focuses on the US Food and Drug Administration (FDA) regulatory approvals of major CPIs and the evolution of translational advances since their first approval close to a decade ago. In addition, critical preclinical and clinical pharmacology considerations, an overview of the pharmacokinetic and dose/regimen aspects, and a discussion of the future of CPI translational and clinical pharmacology as combination therapy becomes a mainstay of industrial immunotherapy development and in clinical practice are also discussed.


  • Open Access

    Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

    by Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L. Quartino, Sandhya Girish, Chunze Li, Whitney P. Kirschbrown

    Purpose: To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa (NCT03493854: fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection [PH FDC SC] versus intravenous pertuzumab plus trastuzumab); derive individual pertuzumab exposures in the PH FDC SC arm for subsequent pertuzumab exposure–response (ER) analyses; compare observed trastuzumab PK with predicted exposures from a previous SC trastuzumab model; assess whether pertuzumab affects trastuzumab PK; evaluate pertuzumab exposure–efficacy and –safety relationships and support the approved SC dosing regimen. Methods: Population pharmacokinetic modeling and simulations were used to describe the data. Standard goodness-of-fit diagnostics and prediction-corrected visual predictive checks were used for model performance assessment. Covariates were included from previously reported models. ER analysis was conducted using logistic regression. Results: SC pertuzumab PK was described adequately by a two-compartment model with first-order absorption; significant covariates included in the final model were albumin, lean body weight, and Asian region; however, these appeared not to be clinically relevant. Trastuzumab concentrations were described adequately by the previous model; there was no evidence of a pertuzumab effect on trastuzumab PK as part of PH FDC SC and higher model-predicted pertuzumab exposure was not associated with differences in pathologic complete response rate or an increased probability of selected grade ≥ 3 adverse events of interest. Conclusion: The approved PH FDC SC dose [loading: 1200/600 mg pertuzumab/trastuzumab (15 mL); maintenance: 600 mg pertuzumab/trastuzumab (10 mL) and 2000 U/mL recombinant human hyaluronidase every 3 weeks] provides a positive benefit–risk profile with comparable efficacy and safety to intravenous pertuzumab plus trastuzumab.


  • Open Access

    Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation

    by Pascal Chanu, Luna Musib, Xin Wang, Sravanthi Cheeti, Sandhya Girish, Rene Bruno, Tong Lu, Josina Reddy, Jin Y. Jin, Ivor Caro